Epoetin-beta/immunosuppressants

2021 ◽  
Vol 1855 (1) ◽  
pp. 153-153
Keyword(s):  
Pharmacology ◽  
1996 ◽  
Vol 52 (5) ◽  
pp. 329-338 ◽  
Author(s):  
H. Bleuel ◽  
R. Hoffmann ◽  
B. Kaufmann ◽  
P. Neubert ◽  
P.-P. Ochlich ◽  
...  

2006 ◽  
Vol 58 (1) ◽  
pp. 46-52 ◽  
Author(s):  
P PRONZATO ◽  
J JASSEM ◽  
J MAYORDOMO
Keyword(s):  

2015 ◽  
pp. 583 ◽  
Author(s):  
Colin Egan ◽  
Luca Galli ◽  
Clara Ricci
Keyword(s):  

2016 ◽  
Vol 20 (4) ◽  
pp. 400-407
Author(s):  
Shang-Chih Liao ◽  
Cheng-Chieh Hung ◽  
Chien-Te Lee ◽  
Chih-Hsiung Lee ◽  
Chin-Chan Lee ◽  
...  

Oncology ◽  
2008 ◽  
Vol 74 (1-2) ◽  
pp. 112-118 ◽  
Author(s):  
Dominique Spaëth ◽  
Bernard Desablens ◽  
Philippe Rodon ◽  
Bertrand Mennecier ◽  
Stéphane Oudard ◽  
...  

2020 ◽  
Author(s):  
Yukiko Yasuoka ◽  
Takashi Fukuyama ◽  
Yuichiro Izumi ◽  
Tetsuro Yamashita ◽  
Yushi Nakayama ◽  
...  

Abstract Doping tests for illegal use of erythropoiesis-stimulating agents (ESAs) have been developed. Here, we show a new Western blotting to distinguish endogenous erythropoietin (Epo, 35-38 kDa) and exogenous ESAs (epoetin alpha and beta; 38-42 kDa, darbepoetin alpha; 47-50 kDa, epoetin beta pegol; 93-110 kDa). In contrast, Liquid Chromatography/Mass Spectrometry analyzed all endogenous Epo and exogenous ESAs as delycosylated 22 kDa Epo, indicating that LC/MS analysis could not distinguish Epo and ESAs. We believe that our Western blotting is useful to protect against illegal use of ESAs.


Sign in / Sign up

Export Citation Format

Share Document